An engineered, compact Cas12m variant for multiplexed gene activation in vivo

Achieving coordinated CRISPR-based transactivation (CRISPRa) regulation in vivo remains challenging, as the requisite genetic elements frequently exceed the packaging capacity of AAV vectors.

By Zhang, Yang, Liu +20Nature biotechnologyOct 28, 2026

Score████░░░░░░4.4

VerdictWorth a reader's time today.

Read the original

Abstract

Achieving coordinated CRISPR-based transactivation (CRISPRa) regulation in vivo remains challenging, as the requisite genetic elements frequently exceed the packaging capacity of AAV vectors. Here we report the identification and engineering of the Cas12m protein family, a naturally nuclease-dead CRISPR system that possesses intrinsic self-processing activity for its precursor crRNA. We develop an optimized variant, denCas12m, and leverage it in the smCRISPRa platform. We show that a single transcriptional unit encoding a multi-gRNA array can be processed into individual functional guides within a target cell, enabling efficient synergistic activation of a single gene through multiple sites or simultaneous activation of distinct endogenous genes from a single all-in-one AAV vector. We demonstrate phenotypic rescue in mouse models of Duchenne muscular dystrophy and Scn1a haploinsufficiency. Furthermore, a single all-in-one AAV vector supports the simultaneous activation of multiple distinct endogenous genes in mice, with a single vector delivering up to eight crRNAs for activation of six different genes, demonstrating the platform's high-order multiplexing.

Hainan Zhang, Lin Yang, Yuling Liu, Dingyi Han, Yingnan Li, Jiajia Lin, Bingyan Wang, Jiaxu Hu, Yaru Zhang, Yi Zhang, Jinhui Li, Shuping Wei, Simiao Liu, Tong Li, Na Zhong, Ganggang Zhang, Xingtao Zhou, Linyu Shi, Jinhai Huang, Hui Yang, Guohe Tan, Yingsi Zhou, Guoling Li

The editor's rubric

Heuristic review

Leverage4 / 5: A general-purpose tool used across several fields (Adam, ResNet, LoRA, next-generation sequencing).; 24% of this desk’s rubric
Magnitude3 / 5: Large gain: roughly 2x, or a clear new state of the art on a hard, unsaturated problem.; 16% of this desk’s rubric
Evidence3 / 5: Solid: multiple benchmarks or cohorts, ablations, fair baselines, released code or data.; 20% of this desk’s rubric
Novelty2 / 5: A new combination of known ideas.; 20% of this desk’s rubric
Trajectory3 / 5: A clear path to scale.; 10% of this desk’s rubric
Stakes2 / 5: Benefits a professional community (practitioners, clinicians, engineers).; 10% of this desk’s rubric

Dimension	Level	Weight	What that level means
Leverage	████░4/5	24%	A general-purpose tool used across several fields (Adam, ResNet, LoRA, next-generation sequencing).
Magnitude	███░░3/5	16%	Large gain: roughly 2x, or a clear new state of the art on a hard, unsaturated problem.
Evidence	███░░3/5	20%	Solid: multiple benchmarks or cohorts, ablations, fair baselines, released code or data.
Novelty	██░░░2/5	20%	A new combination of known ideas.
Trajectory	███░░3/5	10%	A clear path to scale.
Stakes	██░░░2/5	10%	Benefits a professional community (practitioners, clinicians, engineers).

Editor’s rationale

Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: method (we propose, we report); breadth (many tasks, programmable); gains (outperforms); verification (experimental validation); scale (efficient). Red flags: derivative (modified version).

How the score was computed

rank-2026-10-18

Score████░░░░░░4.4

Score = 10 × (75% × adjusted merit / 10 + 15% × attention + 10% × freshness)

Desks place stronger verdicts first, then use this score to order work within the same verdict.

Merit: 5.9 / 10; Weighted rubric, evidence-gated.
Adjusted merit: 4.8 / 10; Shrunk toward the desk prior by editor confidence (44%).
Attention: 0%; Citations, upvotes, points, mentions.
Freshness: 80%; Half-life decay since publication.

Citations0 (reference 20, via openalex, Oct 30, 2026, 05:48 UTC)

The record

Reviewed by heuristic-v10 on Oct 30, 2026, 05:48 UTC. Paper type: method.
Categories: Journal Article
BRIEF, No.1 in the Biology edition of October 30, 2026.